Compare Aurora Cannabis Inc (ACB) vs American International Group Inc (AIG) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

AIG trades at $78.78, down 1.49% on the day, with a neutral technical stance as RSI readings near 42 suggest balanced momentum. The stock shows solid fundamentals with a P/E of 14.38 and recent earnings beats, including Q2 2026 EPS of $2.00 versus $1.92 expected. Revenue stability around $26.8 billion in 2025 and a net income margin of 11.88% reflect disciplined underwriting and expense control, though investment income headwinds persist. Analyst consensus price target is $88.90, implying potential upside, supported by a 39% buy rating among coverage.

Outlook remains cautiously optimistic given earnings consistency and undervaluation relative to peers, but risks include competitive pricing pressure and macroeconomic volatility affecting insurance demand. The dividend yield of approximately 2.5% adds income appeal, yet high beta exposure may lead to amplified swings in broader market downturns, warranting monitoring of Q3 2026 results for sustained growth catalysts.